Neurocognitive Function Following Therapy for Low-Grade Gliomas

Semin Radiat Oncol. 2015 Jul;25(3):210-8. doi: 10.1016/j.semradonc.2015.02.005. Epub 2015 Feb 21.

Abstract

Low-grade gliomas (LGGs) are a heterogenous group of primary brain neoplasms that most commonly occur in children and young adults, characterized by a slow, indolent course and overall favorable prognosis. Standard therapies used to treat LGGs have included surgical resection, radiotherapy, chemotherapy, or a combination thereof. Given the anticipated long survival and typical young age of patients with LGG, the long-term sequelae of therapy require special attention, especially as they affect neurocognitive function and quality of life. We review the complex interplay of baseline and treatment-related factors that perturb neurocognition as well as the effect of each treatment modality on altering neurocognitive outcomes in this patient population.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Brain / drug effects
  • Brain / radiation effects
  • Brain / surgery
  • Brain Neoplasms / therapy*
  • Chemotherapy, Adjuvant / adverse effects
  • Cognition Disorders / etiology*
  • Combined Modality Therapy / adverse effects
  • Glioma / therapy*
  • Humans
  • Radiotherapy / adverse effects
  • Surgical Procedures, Operative / adverse effects